Last updated: 2026-10-13 09:23:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Exicure, Inc. (XCUR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.12, with a market capitalisation of $6.87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.94 to $9.48. This page covers its latest market performance, valuation, price trends and company information.
$6.87M | |
$1.12 | |
$576.00 | |
$0.94 | |
$1.09 | |
18.00 | |
207.06K | |
-- | |
$9.48 | |
$0.94 | |
-- | |
-- |
Exicure, Inc. (XCUR) is trading at $1.12 in pre-market trading as of 2026-10-13 08:51:00, up 2.29% ($0.02) from the previous close of $1.09
Pre-market trading shows how investors are pricing XCUR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Exicure, Inc. (XCUR) moved from $1.15 to $1.12, representing a decline of 3.04% ($0.03).
The stock traded between $0.94 and $1.19 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 55.24 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.1%
XCUR is currently trading at $1.12, placing it 2.1% of the way from its 52-week low of $0.94 to its 52-week high of $9.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Exicure, Inc. (XCUR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.